Haylock D N, Horsfall M J, Dowse T L, Ramshaw H S, Niutta S, Protopsaltis S, Peng L, Burrell C, Rappold I, Buhring H J, Simmons P J
Matthew Roberts Laboratory, Haematology Division, Institute of Medical and Veterinary Science, Adelaide, South Australia.
Blood. 1997 Sep 15;90(6):2260-72.
The ligand for flt-3 (FLT3L) exhibits striking structural homology with stem cell factor (SCF) and monocyte colony-stimulating factor (M-CSF) and also acts in synergy with a range of other hematopoietic growth factors (HGF). In this study, we show that FLT3L responsive hematopoietic progenitor cells (HPC) are CD34+CD38-, rhodamine 123dull, and hydroperoxycyclophosphamide (4-HC) resistant. To investigate the basis for the capacity of FLT3L to augment the de novo generation of myeloid progenitors from CD34+CD38- cells, single bone marrow CD34+CD38- cells were sorted into Terasaki wells containing serum-free medium supplemented with interleukin-3 (IL-3), IL-6, granulocyte colony-stimulating factor (G-CSF), SCF (4 HGF) +/- FLT3L. Under these conditions, FLT3L recruited approximately twofold more CD34+CD38- cells into division than 4 HGF alone. The enhanced proliferative response to FLT3L was evident by day 3 and was maintained at all subsequent time points examined. In accord with these findings, we also show that transduction of CD34+CD38- cells with the LAPSN retrovirus is enhanced by FLT3L. The results of these experiments therefore indicate that increased recruitment of primitive HPC into cell cycle underlies the ex vivo expansion potential of FLT3L and also its ability to improve retroviral transduction of HPC.
Flt-3配体(FLT3L)与干细胞因子(SCF)和单核细胞集落刺激因子(M-CSF)具有显著的结构同源性,并且还能与一系列其他造血生长因子(HGF)协同发挥作用。在本研究中,我们发现对FLT3L有反应的造血祖细胞(HPC)为CD34+CD38-、罗丹明123染色浅,且对氢过氧环磷酰胺(4-HC)具有抗性。为了研究FLT3L增强CD34+CD38-细胞从头生成髓系祖细胞能力的基础,将单个骨髓CD34+CD38-细胞分选至含有补充了白细胞介素-3(IL-3)、IL-6、粒细胞集落刺激因子(G-CSF)、SCF(4种HGF)±FLT3L的无血清培养基的特拉斯基孔板中。在这些条件下,与单独使用4种HGF相比,FLT3L促使进入分裂的CD34+CD38-细胞数量增加了约两倍。对FLT3L的增殖反应增强在第3天就很明显,并在随后所有检测的时间点都得以维持。与这些发现一致,我们还表明FLT3L可增强用LAPSN逆转录病毒对CD34+CD38-细胞的转导。因此,这些实验结果表明,将原始HPC更多地募集到细胞周期中是FLT3L体外扩增潜能及其改善HPC逆转录病毒转导能力的基础。